Administration of short-term immunosuppressive agents after DLI reduces the incidence of DLI-associated acute GVHD without influencing the GVL effect

Bone Marrow Transplantation

Volumn 44, Issue 5, 2009, Pages 309-316

  Huang, X J ^a   Wang, Y ^a   Liu, D H ^a   Xu, L P ^a   Liu, K Y ^a   Chen, H ^a   Chen, Y H ^a   Han, W ^a   Shi, H X ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOSIDE; BASILIXIMAB; CYCLOSPORIN A; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; METHOTREXATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; RISK REDUCTION; SHORT COURSE THERAPY; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; TREATMENT DURATION;

ADOLESCENT; ADULT; CHILD; FEMALE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA; LEUKOCYTE TRANSFUSION; LYMPHOCYTES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70349137580     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.26     Document Type: Article

References (23)

1. Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S et al Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukemia. Br J Haematol 1999; 107: 409-418.
2. Barrett AJ, Locatelli F, Treleaven JG, Gratwohl A, Szydło R, Zwaan FE. Second transplants for leukemic relapse after bone marrow transplantation: High early mortility but favorable effect of chronic GVHD on continued remission. Br J Haematol 1991; 79: 567-574.
3. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working party Chronic Leukemia. Blood 1995; 86: 2041-2050.
4. Collins Jr RH, Goldstein S, Giralt S, Levine J, Porter D, Drobyski W et al. Donor leukocyte infusions in acute lymphocytic leukemia. Bone Marrow Transplant 2000; 26: 511-516.
5. Alessandrino EP, Bernasconi P, Caldera D, Colombo A, Malcovati L, Martinelli G et al. Chemotherapy and donor peripheral blood progenitor cells for acute leukemia in early relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant 1999; 23 607-612.
6. Sohn SK, Jung JT, Kim DH, Lee NY, Seo KW, Chae YS et al. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies. Cancer 2002; 94: 18-24.
7. Huang X, Guo N, Ren H, Zhang Y, Gao Z, Lu D. An improved anti-leukemic effect achieved with donor progenitor cell infusion for relapse patients after allogeneic bone marrow transplantation. Chin Med J 2003; 116: 736-741.
8. Huang XJ, Liu DH, Xu LP, Chen H, Han W, Liu KY et al. Prophylactic infusion of donor granulocyte colony stimulating factor mobilized peripheral blood progenitor cells after allogeneic hematological stem cell transplantation in patients with high-risk leukemia. Leukemia 2006; 20: 365-368.
9. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/ haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica 2007; 92: 414-417.
10. Huang XJ, Wang Y, Liu DH, Xu LP, Chen H, Chen YH et al. Modified donor lymphocyte infusion (DLI) for the prophylaxis of leukemia relapse after hematopoietic stem cell transplantation in patients with advanced leukemia - feasibility and safety study. J Clin Immunol 2008; 28: 390-397.
11. Devergie A. Graft vs host disease. In: Apperley J, Carreras E, Gluckman E, Gratwohl A, Masszi T (eds). Haematopoietic Stem Cell Transplantation: The EBMT Handbook, Rev edn. European School of Hematology: Paris, France, 2004, pp 168-169.
12. Weisdorf D. GVHD - The Nuts and Bolts. In: Gewirtz AM, Winter JN, Zuckerman K (eds). American Society of Hematology Education Program Book. Washington, DC, USA, 2007, pp 62-67.
13. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
14. Slavin S, Naparastek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
15. Huang XJ, Chang YJ, Zhao XY. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral blood grafts and G-CSF primed bone marrow grafts in different proportions. Transplant immunol 2007; 17: 193-197.
16. Huang XJ, Chang YJ, Zhao XY. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004; 89: 1517-1524.
17. Chen SH, Li X, Huang XJ. Effect of recombinant granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004; 79: 178-184.
18. Zeng D, Dejbakhsh-Jones S, Strorber S. Granulocyte colony stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: Impact on blood progenitor cell transplantation. Blood 1997; 90: 453-463.
19. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712-2716.
20. Weisser M, Tischer J, Schnittger S, Schoch C, Ledderose G, Kolb HJ. A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006; 91 663-666.
21. Collins RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusion in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433-444.
22. Kim JG, Sohn SK, Kim DH, Lee NY, Suh JS, Lee KS et al. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant. Bone marrow transplant 2004; 33: 231-236.
23. Schmid C, Labopin M, Nagler A, Bornhäuser M, Finke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: A retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol 2007; 25: 4938-4945.